393 related articles for article (PubMed ID: 36911692)
1. Imaging assessment of toxicity related to immune checkpoint inhibitors.
Berz AM; Boughdad S; Vietti-Violi N; Digklia A; Dromain C; Dunet V; Duran R
Front Immunol; 2023; 14():1133207. PubMed ID: 36911692
[TBL] [Abstract][Full Text] [Related]
2. Adverse effects under immune checkpoint inhibitors on [18F]FDG PET/CT imaging.
Sachpekidis C; Hassel JC; Dimitrakopoulou-Strauss A
Q J Nucl Med Mol Imaging; 2022 Sep; 66(3):245-254. PubMed ID: 35612369
[TBL] [Abstract][Full Text] [Related]
3. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
Eur Urol Focus; 2021 Sep; 7(5):1092-1099. PubMed ID: 33172772
[TBL] [Abstract][Full Text] [Related]
4. Interpretation of 2-[
Manson G; Lemchukwu AC; Mokrane FZ; Lopci E; Aide N; Vercellino L; Houot R; Dercle L
Eur Radiol; 2022 Sep; 32(9):6536-6544. PubMed ID: 35344061
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitor-Related Adverse Effects and
Schierz JH; Sarikaya I; Wollina U; Unger L; Sarikaya A
J Nucl Med Technol; 2021 Dec; 49(4):324-329. PubMed ID: 34330805
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic impact of
Tatar G; Alçin G; Sengul Samanci N; Erol Fenercioglu Ö; Beyhan E; Cermik TF
Clin Transl Oncol; 2022 Oct; 24(10):1903-1913. PubMed ID: 35594002
[TBL] [Abstract][Full Text] [Related]
7. Immune-related adverse events on body CT in patients with small-cell lung cancer treated with immune-checkpoint inhibitors.
Park H; Hatabu H; Ricciuti B; Aijazi SJ; Awad MM; Nishino M
Eur J Radiol; 2020 Nov; 132():109275. PubMed ID: 32949913
[TBL] [Abstract][Full Text] [Related]
8. Abdominal immune-related adverse events: detection on ultrasonography, CT, MRI and 18F-Fluorodeoxyglucose positron emission tomography.
Anderson MA; Kurra V; Bradley W; Kilcoyne A; Mojtahed A; Lee SI
Br J Radiol; 2021 Feb; 94(1118):20200663. PubMed ID: 33112648
[TBL] [Abstract][Full Text] [Related]
9. Imaging for assessment of cancer treatment response to immune checkpoint inhibitors can be complementary in identifying hypophysitis.
Galligan A; Iravani A; Lasocki A; Wallace R; Weppler AM; Sachithanandan N; Chiang C; Colman PG; Wentworth J; Spain L; Au-Yeung G; Lee B; Kay TWH; Hicks RJ; Sandhu S; Krishnamurthy B
Front Endocrinol (Lausanne); 2023; 14():1295865. PubMed ID: 38093958
[TBL] [Abstract][Full Text] [Related]
10. FDG PET/CT for Evaluation of Immunotherapy Response in Lung Cancer Patients.
Léger MA; Routy B; Juneau D
Semin Nucl Med; 2022 Nov; 52(6):707-719. PubMed ID: 35636978
[TBL] [Abstract][Full Text] [Related]
11. PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy.
Gao Y; Wu C; Chen X; Ma L; Zhang X; Chen J; Liao X; Liu M
Front Immunol; 2022; 13():1049043. PubMed ID: 36341331
[TBL] [Abstract][Full Text] [Related]
12.
Cherk MH; Nadebaum DP; Barber TW; Beech P; Haydon A; Yap KS
J Med Imaging Radiat Oncol; 2022 Jun; 66(4):483-494. PubMed ID: 35191204
[No Abstract] [Full Text] [Related]
13. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
[No Abstract] [Full Text] [Related]
14. Radiomics, Tumor Volume, and Blood Biomarkers for Early Prediction of Pseudoprogression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibition.
Basler L; Gabryś HS; Hogan SA; Pavic M; Bogowicz M; Vuong D; Tanadini-Lang S; Förster R; Kudura K; Huellner MW; Dummer R; Guckenberger M; Levesque MP
Clin Cancer Res; 2020 Aug; 26(16):4414-4425. PubMed ID: 32253232
[TBL] [Abstract][Full Text] [Related]
15. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
[TBL] [Abstract][Full Text] [Related]
16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
17. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Chen C; Wu B; Zhang C; Xu T
Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
[TBL] [Abstract][Full Text] [Related]
18. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
[TBL] [Abstract][Full Text] [Related]
19. The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.
Kiamanesh Z; Ayati N; Sadeghi R; Hawkes E; Lee ST; Scott AM
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4661-4676. PubMed ID: 35932329
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy-related adverse effects on
Gandy N; Arshad MA; Wallitt KL; Dubash S; Khan S; Barwick TD
Br J Radiol; 2020 Jul; 93(1111):20190832. PubMed ID: 32105505
[No Abstract] [Full Text] [Related]
[Next] [New Search]